期刊
JOURNAL OF MOLECULAR LIQUIDS
卷 351, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.molliq.2022.118614
关键词
Hyaluronic acid; Serum albumins; Biocolloids; Ibuprofen; Intestinal-PAMPA
资金
- Ministry of Innvation and Technology of Hungary from the National Research, Development and Innovation Fund under the TKP2021-EGA-32 funding scheme [TKP2021-EGA-32]
- NRDIH [FK131446]
- University of Szeged [5598]
- new National Excellence Program of the Ministry for Innovation and Technology from the NRDIF [UNKP-21-4-SZTE-516]
- Janos Bolyai Research Fellowship of the Hungarian Academy of Sciences
The effective applicability of serum albumin-hyaluronic acid (HyA) conjugates as potential drug delivery colloidal particles for encapsulating ibuprofen (IBU) has been demonstrated. These protein/polysaccharide colloidal carriers show improved dissolution, intestinal permeability, and flux features compared to unformulated IBU, making them a more controlled, lower dose loading, and gastric mucosa-sparing therapeutic solution in high-dose IBU therapy.
Effective applicability of serum albumin-hyaluronic acid (HyA) conjugates as potential drug delivery colloidal particles having d similar to 220 - 260 nm average size has been presented for encapsulation of ibuprofen (IBU). Increased IBU content with drug loading of 30 % can be achieved via combination of the serum albumin proteins with biodegradable HyA polysaccharide. After optimization of the synthesis protocols and the characterization of the prepared systems for both bovine (BSA) and human serum albumin (HSA)-based particles, in vitro dissolution and intestinal-specific permeability studies were also performed. It was established that these protein/polysaccharide colloidal carriers have more favourable dissolution, intestinal permeability, and flux features than the unformulated IBU which is greatly controlled by the net charge of serum albumins at pH = 6.50. The nanosized carrier formula, which provides enhanced solubility, accelerated dissolution, and greater permeability, may represent a more controlled, lower dose loading, and gastric mucosa-sparing therapeutic solution in the high-dose IBU therapy. (C) 2022 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据